Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial

doi:10.4254/wjh.v8.i14.625

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9443)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

488

WORD

323

HTML

4347

Figures (1-2)

180

Tables (1-2)

177

Sum=5515

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

413

Download

808

Sum=1221

Publishing Process of This Article

Item

Count

Browse

1070

Download

1637

Sum=2707

May 18, 2016 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

World J Hepatol. May 18, 2016; 8(14): 625-631
Published online May 18, 2016. doi: 10.4254/wjh.v8.i14.625

Full Size Figure Download Figure

Figure 2 Number of patients who became hepatitis D virus RNA negative. HDV: Hepatitis D virus; PEG-IFN: Pegylated interferon.

Citation: Abbas Z, Memon MS, Umer MA, Abbas M, Shazi L. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial. World J Hepatol 2016; 8(14): 625-631
URL: https://www.wjgnet.com/1948-5182/full/v8/i14/625.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i14.625